共查询到19条相似文献,搜索用时 156 毫秒
1.
目的:研究MN/CA9蛋白的表达和肾细胞癌的关系,探讨MN/CA9蛋白在肾细胞癌诊断研究中的应用。方法:应用免疫组化和免疫印迹的方法,对正常肾组织、良性肾损害及肾细胞癌组织的MN/CA9蛋白的表达进行了分析。结果:正常人肾组织和良性肾损害均为MN/CA9阴性,而在30例肾癌中却有28例为MN/CA9阳性,尤其是26例富糖原型RCC均呈现MN/CA9强阳性。结论:MN/CA9蛋白可作为肾细胞癌尤其是 相似文献
2.
目的 :研究MN/CA9蛋白的表达和肾细胞癌的关系 ,探讨MN/CA9蛋白在肾细胞癌诊断研究中的应用。方法 :应用免疫组化和免疫印迹的方法 ,对正常肾组织、良性肾损害和肾细胞癌组织的MN/CA9蛋白的表达进行了分析。结果 :正常人肾组织和良性肾损害均为MN/CA9阴性 ,而在 30例肾癌中却有 2 8例为MN/CA9阳性 ,尤其是 2 6例富糖原型RCC均呈现MN/CA9强阳性。结论 :MN/CA9蛋白可作为肾细胞癌尤其是富糖原型肾细胞癌的一种标志物 相似文献
3.
4.
增殖细胞核抗原在肝细胞癌、肝硬化和慢性肝炎中的表达 总被引:1,自引:0,他引:1
为了观察增殖细胞核抗原在肝细胞癌(HCC)、肝硬化(LC)和慢性活动性肝炎(CAH)中的表达,应用微波内免疫组化技术,对55例HCC切除标本和57例肝穿刺活检标本进行了增殖细胞核抗原(PCNA)单克隆抗体的标记。结果发现,HCC切除标本中PCNA阳性率70.9%(39/55),PCNA标记指数与HCC分级呈正相关,与癌旁组织相比差异显著,在肝穿刺活检标本中,PCNA阳性率:HCC为69.3%(9/13);LC为23.8%(5/21),CAH为8.7%(2/23)。本研究中共检出肝细胞不典型增生27例,标记指数近似于HCCⅠ级,其中小细胞性不典型增生和大细胞性不典型增生的标记指数无差异。 相似文献
5.
目的 探讨DNA结合抑制因子1(Id1)在非小细胞肺癌(NSCLC)发生、发展中的作用及与NSCLC临床病理特征之间的联系。方法 选取30例NSCLC癌组织、癌旁组织和正常肺组织以及10例肺良性病变组织和正常肺组织,采用RT-PCR和免疫组化SP法测定其Id1mRNA和Id1蛋白的表达情况。结果 (1)Id1mRNA、Id1蛋白在NSCLC癌组织中的阳性表达率为96.67%(29/30)、93.33%(28/30),在癌旁组织中的阳性表达率为13.33%(4/30)、10%(3/30),在NSCLC正常肺组织、肺良性病变组织及其正常肺组织中均未见表达。(2)NSCLC癌组织Id1mRNA和Id1蛋白的表达强度随癌细胞分化程度的降低而增强。(3)NSCLC患者Id1mRNA和Id1蛋白的表达与病理类型、瘤体大小、淋巴结转移及预后无明显相关性。结论 Id1因子可能是鉴别NSCLC与肺良性病变的重要分子标记物之一,且其表达水平与NSCLC癌细胞分化程度呈负相关。 相似文献
6.
目的 探讨乳腺癌组织中组蛋白脱乙酰基酶1(HDAC1)和DNA甲基转移酶1(DNMT1)的表达及临床意义。方法 应用组织芯片和免疫组织化学SP法检测105例乳腺癌组织和37例癌旁组织中HDAC1和DNMT1蛋白的表达情况并分析其与ER、PR之间的关系。结果 (1)HDAC1蛋白在105例乳腺癌中的阳性表达率为64.76%,在癌旁组织中的阳性表达率为35.14%,两组差异有统计学意义(P<0.01);DNMT1蛋白在乳腺癌中的阳性表达率为55.24%,在癌旁组织中的阳性表达率为24.32%,两组差异有统计学意义(P<0.01);(2)HDAC1和DNMT1蛋白的表达与患者年龄、瘤体大小、组织学类型、组织学分级、腋窝淋巴结转移、临床分期均无相关性(P>0.05);(3)乳腺癌组织中HDAC1和DNMT1蛋白在ER或PR阴性乳腺癌组织中的表达分别高于其在ER或PR阳性乳腺癌组织中的表达(P<0.01)。HDAC1与DNMT1蛋白表达具有一定的相关性。结论 乳腺癌组织中HDAC1和DNMT1蛋白过表达与肿瘤发生发展密切相关。 相似文献
7.
脑肿瘤中Pten/MMAC1/Tep1蛋白的表达 总被引:5,自引:0,他引:5
目的:探讨Pten/MMAC1/Tep1蛋白在不同分化程度的脑肿瘤组织中的表达。方法:应用免疫组化技术检测30例脑胶质细胞瘤和15例脑膜瘤Pten/MMAC1/Tep1蛋白表达。结果:脑胶质细胞瘤组织中Pten/MMAC1/Tep1蛋白表达阳性率为53.33%,脑膜瘤组织中Pten/MMAC1/ep1蛋白表达阳性率为93.33%,两者差异有显著性(P〈0.01)。结论Pten/MMAC1/Tep1 相似文献
8.
目的 观察TRAIL对肺癌A549细胞的体外生长抑制及诱导凋亡作用,并探讨TRAIL与蛋白酶抑制剂MG132联合用药诱导细胞凋亡的作用及其机制。方法 采用MTT法检测不同浓度TRAIL对肺癌A549细胞增殖的影响;应用流式细胞仪技术检测TRAIL、蛋白酶抑制剂MG132及其两药联合干预24h对肺癌A549细胞凋亡率的影响;采用Westernblotting检测药物干预前后细胞凋亡相关蛋白Caspase-8、Caspase-9以及核转录因子NF-κB的表达情况。结果 MTT结果显示不同浓度TRAIL对肺癌A549细胞的体外抑制作用与剂量效应正相关,24hIC50为96.322μg/ml,48hIC50为43.59μg/ml;流式细胞术显示TRAIL与MG132联合用药后肺癌A549细胞凋亡率明显增高(平均67.65%),与TRAIL(平均23.55%)、MG132(平均25.91%)单药组比较,有显著性差异(P=0.016);Westernblotting结果显示,与TRAIL单药组比较,两药联合后细胞凋亡相关蛋白Caspase-8、Caspase-9表达明显增强(P=0.006),抑制细胞凋亡因子NF-κB表达则明显减弱(P=0.04)。结论 TRAIL可抑制A549细胞的增殖,呈浓度依赖关系;TRAIL与蛋白酶抑制剂MG132联合应用可以明显提高细胞凋亡率,可能与蛋白酶抑制剂MG132降低NF-κB的活性,增强细胞对TRAIL诱导凋亡的敏感性,促进凋亡相关蛋白Caspase-8及Caspase-9的表达有关。 相似文献
9.
为了观察增殖细胞核抗原在肝细胞癌(HCC)、肝硬化(LC)和慢性活动性肝炎(CAH)K 的表达,应用微波内免疫组化技术,对55例HCC切除标本和57例肝穿刺活检标本进行了增殖细胞核抗原(PCNA)单克隆抗体的标记。结果发现,HCC切除标本中PCNA阳性率70.9%(39/55),PCNA标记指数与HCC分级呈正相关,与癌旁组织相比差异显著,在肝穿刺活检标本中,PCNA阳性率:HCC为69.3%(9 相似文献
10.
目的:探讨肿瘤坏死因子(tumornecrosisfactor-α,TNF-α)诱导黏附分子CD44表达的机制。方法:以0、2、20、200ng/ml浓度处理MCF-7细胞,了解对MCF-7细胞增殖以及迁徙的影响。Western-blot方法检测MAPK(JNK、P38、ERK)信号通路中蛋白磷酸化水平的变化;用MAPK抑制剂预处理后,检测CD44表达水平。结果:TNF-α可以改变CD44亚型表达,并促进MCF-7细胞的迁徙能力;TNF-α可以激活JNK信号转导通路,对P38和ERK信号通路无明显激活效应;用特异性的JNK信号通路抑制剂可以阻断TNF-α诱导的CD44蛋白表达水平。结论:TNF-α通过JNK信号通路调节CD44并促进MCF-7细胞的迁徙能力。 相似文献
11.
12.
13.
BACKGROUND: Despite the enormous impact that Papanicolaou (Pap) smear screening has had on the incidence of cervical carcinoma in developed countries, there is still an unacceptably high frequency of occurrence of this cancer. In part, this is due to human error associated with cytologic diagnoses of Pap smears. Also, the use of new sampling devices, such as the cytobrush, has increased the complexity of diagnosing benign and neoplastic cervical cytology. This is particularly apparent in the diagnosis of atypical glandular cells of undetermined significance (AGUS). Approximately 40% of AGUS diagnoses have a corresponding significant lesion at biopsy follow-up, and 60% do not. There is clearly a need for an adjunct to cytologic diagnosis that can readily identify AGUS smears that are diagnostic of significant lesions. The authors have identified the MN/CA9 antigen as a strong candidate for an adjunct biomarker. METHODS: A total of 245 Pap smears of all AGUS diagnostic categories with histologic confirmation were studied. The median age of the patients was 39 years. The Bethesda system classification (AGUS-favor reactive, AGUS-not otherwise specified, and AGUS-favor neoplastic) was used. All of the Pap smears were decolorized and immunostained with monoclonal antibody to MN/CA9 antigen by the immunoperoxidase technique. The results of MN/CA9 immunoreactivity were correlated with the histologic data in a semiblinded fashion. RESULTS: The follow-up biopsies showed that a high percentage (70%) of patients had low and high grade cervical intraepithelial neoplasia lesions, respectively (CIN I and CIN II or III). Clinically significant lesions-adenocarcinoma in situ/carcinoma (AIS/CA) and CIN II or III-were found in 50% of the cases. Among these, 11% were AIS/CA. In the three subcategories of AGUS diagnosis, the AGUS-not otherwise specified showed the broadest range of lesions in the follow-up biopsies. Three patterns of MN/CA9 immunoreactivity were observed in the Pap smears: 1) atypical cells, 2) normal endocervical cells only, and 3) all cells negative. All Pap smears that were MN/CA9 positive were histologically confirmed to be clinically significant lesions or CIN I; in addition, there were a very small number (n = 12) of cases of atypia. None of the benign lesions showed MN/CA9 expression in the corresponding Pap smears. Furthermore, the pattern of atypical cell immunostaining identified all cases with significant lesions (AIS/CA and CIN II or III) in the cervices. Conversely, the majority of CIN I cases (82%) and all cases of atypia showed positive immunostaining restricted to normal endocervical cells only. CONCLUSIONS: There is a clear association between MN/CA9 immunostaining of atypical cells and the presence of significant lesions in the cervix. Similarly, there is a clear association between lack of expression of MN/CA9 and the absence of cervical lesions. However, the screen does not allow discrimination between CIN I and atypia. The authors also found that, based on the combined patterns of morphology and immunostaining, they are able to discriminate between AIS and CIN II or III in AGUS Pap smear diagnoses. Thus, expression of the MN/CA9 antigen is indeed a discriminator of significant lesions in AGUS Pap smear diagnoses. 相似文献
14.
G Li K Passebosc-Faure C Lambert A Gentil-Perret F Blanc E Oosterwijk J F Mosnier C Genin J Tostain 《Clinical cancer research》2001,7(1):89-92
Monoclonal antibody (mAb) G250 is a well characterized and specific mAb to renal cell carcinoma (RCC). The gene G250 was recently cloned and was proved to be homologous to MN/CA9. The G250/MN/CA9 antigen was recently explored as a potential marker for RCC. Flow cytometry (FCM) allows quantitative analysis of cells. The present study describes a flow cytometric method to detect this antigen in human cell lines and in malignant and normal renal tissues. Twelve human carcinoma cell lines (HeLa, Colo205, HT29, BxPC3, OVCAR3, SKOV3, ACHN, A704, CAKI-2, SKRC-59, SKRC-10, and SKRC-52), 10 specimens of normal peripheral blood mononuclear cells, and 38 malignant and 36 adjacent normal renal tissues were studied. The malignant and normal renal tissues were disaggregated mechanically into a single-cell suspension, stained by mAb G250, and analyzed by FCM. All 22 of the clear cell carcinomas, 6 of 8 mixed cell carcinomas, and 3 of 6 granular cell carcinomas were positive for G250/MN/CA9 antigen. SKRC-52 and SKRC-10 were strongly positive for G250/ MN/CA9. The G250/MN/CA9 antigen could also be detected in HeLa, SKOV3, HT29, and A704 cells. One chromophobic, one chromophilic cell carcinoma, the normal renal tissues, and normal peripheral blood mononuclear cells were considered as negative. Our results further confirmed that the G250/MN/CA9 antigen was an ideal marker for RCC, especially for clear cell carcinomas, and that this antigen was present in several types of malignant cells. FCM may serve as a fast tool of immunocytochemical detection of renal cancer cells. Flow cytometric detection of renal cancer cells by using mAb G250 should be further explored. 相似文献
15.
Renal cell carcinoma has a very poor prognosis since various therapeutic modalities other than radical operation are not effective. Early detection and treatment are of considerable importance to cure the patients; however, early diagnosis of renal cell carcinoma is not easy because no specific tumor marker, like PSA for prostate cancer, is available. MN/CA9 is considered to be one of the carbonic anhydrase isoenzymes, and is expressed in approximately 90% of renal cell carcinomas. Expression of MN/CA9 in normal tissues is very limited. Using optimal RT-PCR with specific primers, MN/CA9 positive cells were clearly detected in the blood. The sensitivity and specificity were found to be approximately 40% and 90% respectively. The detection of circulating renal cell carcinoma cells using RT-PCR for MN/CA9 mRNA is useful for diagnosis of the presence of renal cell carcinomas. This RT-PCR assay may also be able to provide information with which to predict the prognosis of the patients. 相似文献
16.
Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma 总被引:7,自引:0,他引:7
Cho M Uemura H Kim SC Kawada Y Yoshida K Hirao Y Konishi N Saga S Yoshikawa K 《British journal of cancer》2001,85(4):563-567
MN/CA9 is a cancer-related gene, frequently activated in human renal cell carcinomas (RCCs). To reveal the activation mechanism, we investigated the relationship between methylation status of the MN/CA9 promoter region and gene expression using 13 human RCCs, and examined the effect of in vitro CpG methylation on the MN/CA9 promoter activity using a human RCC cell line (SK-RC-44), expressing MN/CA9. MN/CA9 expression was evaluated by RT-PCR and observed in 10 of 13 RCCs (77%). A total of 9 out of 10 MN/CA9 -positive RCCs (90%) contained clear cell components. Methylation status of 6 CpGs in the MN/CA9 promoter region was decided by using the bisulfite genomic sequencing protocol. Out of 13 RCCs 9 (69%) showed partial hypomethylation of the CpG at -74 bp, while the other 4 RCCs and 3 normal kidney tissue samples showed complete methylation. Hypomethylation of the CpG at -74 bp was strongly correlated with MN/CA9 expression. Luciferase assay revealed that the MN/CA9 promoter activity was strongly suppressed by methylation of the CpG at -74 bp. These findings suggest that hypomethylation of the CpG at -74 bp in the MN/CA9 promoter region might play an important role in this gene activation of human RCC. 相似文献
17.
Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. 总被引:2,自引:0,他引:2
Guorong Li Muriel Cuilleron Anne Gentil-Perret Michèle Cottier Karine Passebosc-Faure Claude Lambert Christian Genin Jacques Tostain 《Clinical cancer research》2003,9(17):6441-6446
18.
Uemura H Nakagawa Y Yoshida K Saga S Yoshikawa K Hirao Y Oosterwijk E 《British journal of cancer》1999,81(4):741-746
19.
目的:研究外周血肿瘤异常糖链糖蛋白(tumor abnormal protein,TAP)的表达对早期肾癌的诊断价值。方法:对45例肾癌患者(肾癌组)、32例肾脏良性病变患者(肾良性病变组)和42例体检健康人群(正常组)的外周血TAP值进行分析;绘制受试者工作特征(receiver operating characteristics,ROC)曲线评估TAP对肾癌的诊断效能;分析肾癌组中TAP阳性表达与患者临床病理特征的关系。结果:肾癌组中外周血TAP水平明显高于肾良性病变组和正常组。通过评估TAP对肾癌的诊断效能,发现TAP诊断肾癌的ROC曲线下面积为0.92(95%CI:0.82~0.95),其诊断肾癌的灵敏度和特异度分别为73%和91%。结论:肾癌患者外周血中TAP呈高表达,可作为肾癌早期诊断的肿瘤标志物。 相似文献